NeurAxis, Inc.

AMEX:NRXS

Biotechnology

Healthcare
$4.87 +4.25%

+$0.29 today

Market cap
$69.12M
Beta
1.41
P/E (TTM)
-10.5
EPS (TTM)
-$0.67
52W Low $2.20High $9.33

Volume 0.23M

Average 0.18M

NRXS Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

NeurAxis, Inc.AMEX: NRXS

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 58.7% from a year ago

Common stock stood at $11.45K at the end of Q1 FY2026, up 58.7% from a year earlier and up 7.5% from the prior quarter. Over 3 fiscal years it compounded at +75.7% a year.

Context

  • Common stock amounted to 0.1% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
  • Common stock increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +58.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.45K+7.5% QoQ
Last fiscal yearDec 2025
$10.65K+52.4% YoY
Year agoMar 2025
$7.22K+58.7% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.7%——
1 year+52.4%——
3-year CAGR+75.7%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
10.65K USD
Year-over-year change
+52.4%
4-year CAGR
+43.0%

Common Stock vs competitors

How NRXS compares with its peers on the latest reported figures

  • NRXS's Mar 2026 common stock of $11.45K is the 2nd highest of the 4 companies compared; the peer median is $4.72K.
  • Its year-over-year change of +58.7% is the 3rd highest of 4, against a peer median of +575.7%.
  • Common stock amounts to 0.1% of total assets for NRXS, versus a peer median of 0.0%.
NRXS Competitors Peer median
Common Stock for NRXS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ENLVEnlivex Therapeutics Ltd.Dec 2025$28.73M +970.0%+138.5%1.2%
NRXSNeurAxis, Inc.Mar 2026$11.45K +58.7%+75.7%0.1%
NERVMinerva Neurosciences, Inc.Jun 2026$4.72K +575.7%+100.9%0.0%
RLYBRallybio CorporationMar 2026$4K +0.0%+0.0%0.0%
Peer median (excluding NRXS) $4.72K+575.7%+100.9%0.0%

Competitors are the stored peer set for NRXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents320.86K253.7K78.56K3.7M4.97M
Short-term Investments00000
Net Receivables115.3K174.4K73.17K244.62K195.7K
Inventory39.18K48.13K21.22K44.33K257.13K
Other Current Assets072669.66K280.37K70.59K
Total Current Assets491.01K476.96K242.61K4.27M5.73M
Property, Plant & Equipment (Net)245.52K189.39K158.82K374.64K337.13K
Goodwill00000
Intangible Assets23.96K77.56K108.07K96.59K274.78K
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0736.74K020.16K58.94K
Total Non-current Assets269.47K1M266.89K491.39K670.85K
Total Assets760.48K1.48M509.5K4.76M6.4M
Account Payables483.79K1.59M1.2M596.95K139.37K
Short-term Debt250.41K489.23K148.06K154.15K148.29K
Tax Payables563777000
Deferred Revenue69.34K59.17K74.95K32.53K28.66K
Other Current Liabilities43.84K4.51M341.7K1.27M2.07M
Total Current Liabilities1.42M6.98M1.89M2.43M2.79M
Long-term Debt51.69K0000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities000010K
Total Non-current Liabilities161.29K76.2K27.07K256.5K212.57K
Total Liabilities1.59M7.05M1.91M2.69M3M
Common Stock2.55K1.96K6.51K6.99K10.65K
Retained Earnings(29.15M)(33.93M)(48.56M)(56.8M)(64.6M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(825.66K)(5.57M)(1.4M)2.07M3.4M
Total Debt439.28K598.82K224.26K473.41K416.61K
Net Debt118.42K345.12K145.7K(3.22M)(4.55M)

NeurAxis, Inc.

AMEX:NRXS

Intrinsic Alpha fair value

Locked

Current Price

$4.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.